ONCOtherapeutics Diversity, Equity, and Inclusion Strategy

At ONCOtherapeutics, we are committed to fostering a workplace environment that values diversity, equity, and…

A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)

A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple…

A phase I trial of selinexor, ruxolitinib and methylprednisolone for patients with relapsed/refractory multiple myeloma

A phase I trial of selinexor, ruxolitinib and methylprednisolone for patients with relapsed/refractory multiple myeloma…

IMBCR & Emory University’s Big Discovery!

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response…

James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center

New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…